261 related articles for article (PubMed ID: 20338905)
1. A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug.
Berry SM; Spinelli W; Littman GS; Liang JZ; Fardipour P; Berry DA; Lewis RJ; Krams M
Clin Trials; 2010 Apr; 7(2):121-35. PubMed ID: 20338905
[TBL] [Abstract][Full Text] [Related]
2. A bayesian dose-finding design adapting to efficacy and tolerability response.
Padmanabhan SK; Berry S; Dragalin V; Krams M
J Biopharm Stat; 2012; 22(2):276-93. PubMed ID: 22251174
[TBL] [Abstract][Full Text] [Related]
3. Bayesian adaptive dose-finding studies with delayed responses.
Fu H; Manner D
J Biopharm Stat; 2010 Sep; 20(5):1055-70. PubMed ID: 20721791
[TBL] [Abstract][Full Text] [Related]
4. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
Xie F; Ji Y; Tremmel L
Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
[TBL] [Abstract][Full Text] [Related]
5. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
6. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
7. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
8. Bayesian dose selection design for a binary outcome using restricted response adaptive randomization.
Meinzer C; Martin R; Suarez JI
Trials; 2017 Sep; 18(1):420. PubMed ID: 28886745
[TBL] [Abstract][Full Text] [Related]
9. Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma.
Hirakawa A; Nishikawa T; Yonemori K; Shibata T; Nakamura K; Ando M; Ueda T; Ozaki T; Tamura K; Kawai A; Fujiwara Y
Ther Innov Regul Sci; 2018 May; 52(3):334-338. PubMed ID: 29714533
[TBL] [Abstract][Full Text] [Related]
10. Paradigms for adaptive statistical information designs: practical experiences and strategies.
Wang SJ; Hung HM; O'Neill R
Stat Med; 2012 Nov; 31(25):3011-23. PubMed ID: 22927234
[TBL] [Abstract][Full Text] [Related]
11. A Bayesian response-adaptive dose-finding and comparative effectiveness trial.
Heath A; Yaskina M; Pechlivanoglou P; Rios D; Offringa M; Klassen TP; Poonai N; Pullenayegum E
Clin Trials; 2021 Feb; 18(1):61-70. PubMed ID: 33231105
[TBL] [Abstract][Full Text] [Related]
12. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
[TBL] [Abstract][Full Text] [Related]
13. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.
Murphy P; Moline M; Mayleben D; Rosenberg R; Zammit G; Pinner K; Dhadda S; Hong Q; Giorgi L; Satlin A
J Clin Sleep Med; 2017 Nov; 13(11):1289-1299. PubMed ID: 29065953
[TBL] [Abstract][Full Text] [Related]
14. Dose-toxicity models in oncology.
Adamina M; Joerger M
Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):201-11. PubMed ID: 21241201
[TBL] [Abstract][Full Text] [Related]
15. Development of a Bayesian response-adaptive trial design for the Dexamethasone for Excessive Menstruation study.
Holm Hansen C; Warner P; Parker RA; Walker BR; Critchley HO; Weir CJ
Stat Methods Med Res; 2017 Dec; 26(6):2681-2699. PubMed ID: 26423728
[TBL] [Abstract][Full Text] [Related]
16. Adaptive Design: A Review of the Technical, Statistical, and Regulatory Aspects of Implementation in a Clinical Trial.
Cerqueira FP; Jesus AMC; Cotrim MD
Ther Innov Regul Sci; 2020 Jan; 54(1):246-258. PubMed ID: 32008232
[TBL] [Abstract][Full Text] [Related]
17. A robust Bayesian dose-finding design for phase I/II clinical trials.
Liu S; Johnson VE
Biostatistics; 2016 Apr; 17(2):249-63. PubMed ID: 26486139
[TBL] [Abstract][Full Text] [Related]
18. Novel clinical trial designs for the development of new antiretroviral agents.
Mani N; Murray J; Gulick RM; Josephson F; Miller V; Miele P; Strobos J; Struble K
AIDS; 2012 May; 26(8):899-907. PubMed ID: 22301412
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian adaptive phase I-II trial design for optimizing the schedule of therapeutic cancer vaccines.
Cunanan KM; Koopmeiners JS
Stat Med; 2017 Jan; 36(1):43-53. PubMed ID: 27545299
[TBL] [Abstract][Full Text] [Related]
20. Adaptive designs in critical care trials: a simulation study.
Li W; Cornelius V; Finfer S; Venkatesh B; Billot L
BMC Med Res Methodol; 2023 Oct; 23(1):236. PubMed ID: 37853343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
